Valproic acid (VPA), used to treat bipolar mood disorder and seizures, also inhibits histone deacetylase (HDAC). Here, we found that VPA and other HDAC inhibitors, butyrate and trichostatin A, robustly protected mature cerebellar granule cell cultures from excitotoxicity induced by SYM 2081 ((2S, 4R)-4-methylglutamate), an inhibitor of excitatory amino-acid transporters and an agonist of low-affinity kainate receptors. These neuroprotective effects required protracted treatment and were correlated with enhanced acetylated histone levels, indicating HDAC inhibition. SYM-induced excitotoxicity was blocked by MK-801 ((5R,10S)-( þ )-5-methyl-10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5,10-imine hydrogen maleate), supporting that the toxicity was largely N-methyl-D-aspartate receptor dependent. SYM excitotoxicity had apoptotic characteristics and was prevented by a caspase inhibitor. SYMinduced apoptosis was associated with a rapid and robust nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a housekeeping gene previously shown to be proapoptotic. VPA pretreatment suppressed SYM 2081-induced GAPDH nuclear accumulation, concurrent with its neuroprotective effects. Chromatin immunoprecipitation (ChIP) revealed that GAPDH is copresent with acetylated histone H3, including Lys9-acetylated histone, and that VPA treatment caused a time-dependent decrease in the levels of nuclear GAPDH with a concomitant increase in acetylated histones in the ChIP complex. Our results strongly suggest that VPA protects neurons from excitotoxicity through inhibition of HDAC activity and that this protective effect may involve suppression of excitotoxicity-induced accumulation of GAPDH protein in the nucleus.
INTRODUCTION
Valproic acid (VPA, 2-propylpentanoic acid) has been used in the therapy of seizures (for a review, see Johannessen sen 1 ). VPA is also known to be a potent teratogen in humans and rodent animal models. Structural and functional studies of VPA and related compounds suggest that the teratogenic and anticonvulsant effects of VPA can be separated and therefore may be mediated by distinct mechanisms. In addition, VPA has clinical efficacy for the treatment of bipolar mood disorder (also referred to as manic depressive illness). VPA and lithium are two primary drugs used for the treatment and prophylaxis of mania and depression, and VPA was often found to be effective in patients resistant to lithium therapy (for a review, see Post et al 2 ) . The mechanisms underlying the therapeutic effects of mood stabilizers are unclear. However, the requirement of protracted treatment for the beneficial effects to appear suggests that regulation of gene expression is a contributor to clinical efficacy.
VPA was recently found to be a direct inhibitor of histone deacetylase (HDAC) in clinically relevant concentrations. 3, 4 HDAC has been catalogued into three classes (for a review, see Gray and Ekstrom 5 ) . Class I HDACs consist of HDAC 1, 2, 3, and 8, whereas Class II HDACs include HDAC 4, 5, 6, 7, 9, and 10. Class III HDACs are structurally unrelated to the human Class I and II HDACs, but consist of homologues of the yeast Sir2 protein. Class I and II HDACs, but not Class III HDACs, are known to be inhibited by short-chain fatty acids (eg VPA and butyrate) and hydroxamic acid (eg trichostatin A (trichostatin A (4,6-dimethyl-7-[p-dimethylaminophenyl]-7-oxohepta-2,4-dieno-hydroxamic acid), TSA)). Accumulating evidence supports the notion that hyperacetylation of histone induced by HDAC inhibitors causes antiproliferation and reversal of neoplastic characteristics through induction of genes involved in cell cycle and morphology. 6 Moreover, HDAC inhibitors were found to induce apoptosis characterized by typical morphological changes. 7, 8 Conversely, HDAC inhibitors were reported to be neuroprotective via enhancing the acetylation of SP1, a cytoprotective transcription factor, and that this process is necessary for the induction of antioxidant proteins. 9 Further, an HDAC inhibitor, phenylbutyrate, was found to prolong markedly life span in Drosophila, presumably through modulation of gene expression. 10 Emerging evidence suggests that VPA is neuroprotective as exemplified by inhibition of some forms of apoptosis (for a review, see Loy and Tariot 11 ). VPA also protects against cell death induced by the stress on endoplasmic reticulum in C 6 glioma cells. 12 In addition, VPA induces axonal remodeling and synapsin clustering, presumably through indirect inhibition of glycogen synthase kinase-3 (GSK-3). 13 The present study was undertaken to investigate the neuroprotective effects of VPA and its underlying mechanisms against excitotoxicity induced by SYM 2081 ((2S, 4R)-4-methylglutamate), an inhibitor of excitatory amino-acid transporters (EAATs) 14 and an agonist of low-affinity kainate receptors, 15 in mature cerebellar granule cells (CGC). We also examined whether the neuroprotective effects of VPA were mimicked by inhibitors of HDAC and were associated with hyperacetylation of histone. In addition, we studied the role of the nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a proapoptotic protein, in the excitotoxicity and VPA neuroprotection. Preparation of CGC and drug treatment CGC were prepared from 8-day-old Sprague-Dawley rat pups as described. 16 Cells were seeded at a density of 2.0 Â 10 5 cells/cm 2 onto 96-well plates precoated with poly-L-lysine and cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% FCS, 50 g/ml gentamicin, and 25 mM KCl. Cytosine-D-arabinofuranoside (10 mM) was added 24 h after plating to arrest the growth of nonneuronal cells. For routine neuroprotective studies, VPA, butyrate, or TSA at indicated concentrations were added to the cultures starting from 7 days in vitro (7-DIV), unless otherwise indicated. SYM 2081 (SYM) was added to the cultures on 13-DIV to trigger neuronal death. Cell viability was determined 24 h later by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays (see below).
MATERIALS AND METHODS

Measurement of Neurotoxicity
Cell viability was determined by measuring the activity of cellular dehydrogenase that cleaves MTT in a colormetric assay as described. 16 Active dehydrogenase reduced MTT in viable cells to form insoluble formazan, which was then dissolved in dimethylsulfoxide and quantified spectrophotometrically at 540 nm. Data represent the means7SEM of % of control from three to four separate experiments. Statistical significance was determined using analysis of variance (ANOVA) unless noted elsewhere. A P-value of p0.05 was considered significant.
Morphological and Immunohistochemical Studies
For DNA staining with 4,6-diaminodiphenyl-2-phenylindole (DAPI), the cells were washed with phosphate-buffered saline (PBS; pH 7.4) and fixed for 10 min in 4% paraformaldehyde in PBS. After fixation, cells were washed with PBS, stained for 20 min with 10 mg/ml DAPI, and washed again with PBS. Fluorescence was detected by UV light microscopy.
For GAPDH immunostaining, the cells were washed with warm PBS and fixed for 15 min in 4% paraformaldehyde in PBS. After fixation, cells were washed with PBS and incubated with a purified polyclonal rabbit anti-GAPDH antibody at 1 : 5000 dilution (gifted by Dr. Akira Sawa) in PBS containing 0.1% Triton X-100 and 5% normal donkey serum for 2 h at room temperature. Signal visualization was performed using donkey anti-rabbit secondary antibody conjugated to rhodamin (1 : 200 dilution; Chemicon, CA, USA). Fluorescence was detected by confocal laser-scanning microscopy together with differential interference contrast imaging of the same field.
Western Blotting
Cells cultured in 100 mm 2 dishes were detached by scraping and sonicated 30 s in sampling buffer containing 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, 5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride (PMSF), 0.2 U/ml aprotinin, 50 mg/ml leupeptin, and 10 mg/ml pepstatin A. Proteins were separated by 10% SDS-PAGE and then transferred onto a PVDF membrane (Millipore, Bedford, MA, USA). Blots were incubated with primary antibodies against acetylated histone H3, acetylated histone H3 on lysine9 (Upstate Biotechnology, Charlottesville, VA, USA), dimethylated histone H3 on lysine9 (Upstate Biotechnology), or GAPDH (Gifted by Dr Akira Sawa), and then probed with a horseradish peroxidase-conjugated secondary antibody. Detection was performed by using enhanced chemiluminescence (ECL kit, Amersham Pharmacia Biotech., NJ, USA).
Nuclear Preparation
The procedures were essentially as described previously. 16 CGC cultured in 100-mm dishes were gently rinsed twice with ice-cold PBS containing 1 mM PMSF, 1 mg/ml aprotinin, and 1 mg/ml pepstatin A, and resuspended in 500 ml lysis buffer (250 mM sucrose, 20 mM Tris-HCl, 10 mM KCl, 2 mM EDTA, 1.5 mM MgCl 2 , 1 mM dithiothreitol (DTT), 0.2 mg/ml leupeptin, 1 mg/ml pepstatin A, and 0.1 mM PMSF). After scraping into a Dounce homogenizer (Wheaton, NJ, USA) and incubating for 30 min on ice, the cells were vigorously homogenized by 60 strokes with a tight-fitting pestle. The nuclei were isolated by discontinuous gradient centrifugation (800 g, 20 min). The supernatant was discarded, and the nuclear pellet was washed with lysis buffer and centrifuged again. The nuclear pellet was resuspended by sonication in SDS-containing sampling buffer for Western blotting of GAPDH protein. All steps were performed at 41C.
Chromatin Immunoprecipitation (ChIP) Assay
To study interactions between DNA-binding protein and proteins of interest, ChIP assay in combination with Western blotting was performed essentially as described previously 17 using a ChIP assay Kit (Upstate Biotechnology) with some modifications. CGC cultured on 10-cm dishes were treated with 1% formaldehyde for 10 min at 371C to crosslink histones to DNA. The medium was aspirated and crosslinked cells were washed twice with ice-cold PBS containing protease inhibitors (1 mM PMSF, 1 mg/ml aprotinin, and 1 mg/ml pepstatin A). Cells were scraped from the plates in PBS and centrifuged for 5 min at 700 g at 41C. The cell pellets were resuspended in 200 ml of SDS Lysis Buffer (Upstate Biotechnology) containing the protease inhibitors as indicated above for 10 min on ice. Cell lysates were sonicated for a total time of 60 s at 10 s/interval to shear chromatin. The supernatant fraction (200 ml) of 12 000 g was diluted 10-fold in ChIP dilution buffer containing the same protease inhibitors. To reduce nonspecific background, 80 ml of salmon sperm DNA/protein A agarose slurry was added to the chromatin solution followed by incubation at 41C for 2 h. The beads were spun down and supernatant fractions were incubated with anti-acetylated histone H3 antibody at 41C for 12 h. The immunocomplex was collected by centrifugation after 2 h incubation at 41C with 60 ml of salmon sperm DNA/protein A agarose slurry. The protein A agarose/antibody/acetylated histone H3 complex was sequentially washed with 1 ml of low-salt immunocomplex wash buffer, high-salt immunocomplex wash buffer, LiCl immunocomplex wash buffer and 1 Â TE. The immunocomplex was eluted by adding 25 ml SDS sample buffer containing 5 mM DTT and boiling with agitation for 5 min. An aliquot of 20 ml was used for Western blotting as described in the previous section and probed with anti-acetylated histone H3 (Upstate Biotechnology), anti-acetylated histone H3 Lys9, and anti-GAPDH antibodies.
RESULTS CGC cultured in DMEM were treated on 13-DIV with 100 mM SYM 2081 (SYM), a purported glutamate transporter blocker and glutamate receptor agonist, which induced more than 60% loss of cell viability after 24 h exposure ( Figure 1a ). This SYM-induced cell death was completely blocked by the presence of MK-801 (an N-methyl-Daspartate (NMDA) receptor antagonist), but was only slightly blocked by the copresence of NBQX (a non-NMDA receptor antagonist) and GYKI 52466 (a kainate/AMPA (aamino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptor antagonist). On the other hand, Ac-DEVD-CHO (a preferential caspase-3 inhibitor) robustly suppressed SYM toxicity, suggesting that this form of toxicity occurs through apoptotic mechanisms. DNA staining with DAPI revealed that SYM treatment caused chromatin condensation and nuclear fragmentation in CGC compared with the untreated control (Figure 1b) .
Pretreatment of CGC with VPA for 6 days starting from 7-DIV induced a concentration-dependent suppression of cell death induced by exposure to SYM for 24 h (Figure 2a) . The neuroprotective effect of VPA was significant at 0.2 mM and enhanced progressively by increasing the drug concentration with a near-complete protection at 1.6 mM. Pretreatment of CGC with VPA alone did not affect cell viability in the concentration range of 0.2-1.6 mM. To examine whether VPA-induced neuroprotection may be related to its ability to inhibit HDAC, we tested the effects of two other HDAC inhibitors, butyrate and TSA. Similar to the effects of VPA, butyrate and TSA pretreatment for 6 days protected CGC from excitotoxicity in a concentration-dependent manner (Figure 2b and c) . The effective concentration ranges were 0.125-1.0 mM for butyrate and 25-100 nM for TSA. We also examined the effects of valpromide and 2-methyl-2-pentenoic acid, two VPA analogs inactive in blocking HDAC activity. 3 Neither drug in the concentration range of 0.2-1.6 mM was found to be effective in protecting CGC from SYM-induced excitotoxicity following a 6-day pretreatment period starting from 7-DIV (data not shown).
VPA (1.6 mM)-induced neuroprotection against SYM toxicity required protracted treatment (Figure 3a) . Pretreatment for one day was ineffective, while 3-7 days of pretreatment produced a significant and progressive increase in neuroprotection. Similar time-dependent neuroprotective effects were observed when cells were pretreated with butyrate (1 mM) or TSA (100 nM) (Figure 3b and c) . VPA, butyrate, and TSA also time and dose dependently protected against glutamate (100 mM)-induced, NMDA receptor-mediated excitotoxicity in CGC (data not shown). To ascertain that HDAC was inhibited in CGC treated with TSA or VPA, cells were harvested on DIV-13 after treatment with TSA (100 nM) or VPA (1.6 mM) for 2-6 days. The results showed that both TSA and VPA markedly enhanced the levels of acetylated histone H3 on Lys9 (Figure 4a ). These effects were time dependent with a more robust effect for VPA than for TSA. In contrast, levels of methylated histone H3, total histone H3 protein, and total GAPDH protein were unaffected by either TSA or VPA.
Adding VPA on 7-DIV and harvesting cells on 9-, 11-, and 13-DIV also resulted in a time-dependent increase in the levels of acetylated histone H3 compared with respective controls (Figure 4b ). In contrast, basal levels of nuclear GAPDH protein were not changed by VPA compared with respective time points of the control. Previous studies have shown that nuclear translocation of GAPDH is involved in apoptosis induced by a variety of insults in neurons and non-neuronal cells. 16, [18] [19] [20] However, the role of GAPDH in excitotoxicity-related cell death has not been reported. Therefore, we first performed immunohistochemical staining with a GAPDH-specific antibody to show that GAPDH was accumulated in the nuclei of CGC stimulated with SYM for 8 h and that this process was associated with cell shrinkage ( Figure 5A ). VPA pretreatment for 6 days blocked SYM-induced GAPDH nuclear accumulation with little or no effect on basal levels of nuclear GAPDH. We then measured the levels of GAPDH protein by Western blotting in nuclear preparations from CGC treated with SYM with or without VPA pretreatment. SYM induced a marked increase in nuclear GAPDH levels 8 h after stimulation ( Figure 5B ). This GAPDH nuclear accumulation was associated with a decrease in GAPDH protein in the cytosolic (10 000 g supernatant) fraction, thus suggesting nuclear translocation (data not shown). VPA pretreatment blocked SYM-induced increase in nuclear GAPDH protein. To determine whether nuclear GAPDH interacts with DNA and a protein complex containing acetylated histone, we performed ChIP assays using 13-DIV CGC fixed with formaldehyde. The ChIP complexes isolated with a polyclonal antibody preparation that recognized acetylated histone H3 of approximately 17 kDa were then subjected to SDS-PAGE and immunoblotted with anti-GAPDH, anti-total-acetylated histone H3, and anti-Lys9-acetylated histone H3 antibodies. The results showed that GAPDH was present in the ChIP complex containing acetylated histone H3, including Lys9-acetylated histone H3 (Figure 6 ). Moreover, VPA treatment rapidly and robustly decreased levels of GAPDH in the ChIP complex with a concomitant increase in the levels of acetylated histone H3.
DISCUSSION
The present study demonstrates that long-term VPA treatment has neuroprotective effects against SYM-induced Figure 3 VPA, butyrate, and TSA protect CGC from SYM excitotoxicity in a time-dependent manner. VPA (1.6 mM), butyrate (1 mM), or TSA (100 nM) was added to CGC cultures at different DIV to achieve different days of pre-exposure time. All cells were treated with SYM (100 lM) on 13-DIV and cell viability was measured 24 h later. Data are means7SEM of % of cell viability of vehicle control. **Po0.01, ***Po0.001 compared with the group of SYM alone. excitotoxicity in CGC. This VPA-induced neuroprotection occurred at therapeutic concentrations used for the treatment of bipolar mood disorder and seizures and was mimicked by other HDAC inhibitors such as butyrate and TSA. The inhibition of HDAC by VPA and TSA was verified by the time-dependent accumulations of acetylated histone H3 protein induced by these two drugs in CGC. These results strongly suggest that VPA-induced neuroprotection involves inhibition of HDAC activity. HDACs include three major classes and more than 10 different subtypes. The subtypes of HDACs involved in the neuroprotective effects of VPA, butyrate, and TSA shown in this study require future investigation. SYM-induced excitotoxicity of CGC showed cell shrinkage, chromatin condensation, and nuclear fragmentation, and was blocked by a caspase-3-prefering inhibitor. These observations suggest that the death of CGC is due, at least in part, to apoptosis. SYM-induced excitotoxicity in CGC was completely blocked by an NMDA receptor antagonist, MK-801, reminiscent with the finding that glutamate or domoic acid-induced Ca 2 þ influx and toxicity in CGC is preferentially blocked by NMDA receptor blockers. 21, 22 Our results suggest that SYM-induced apoptosis is due to the accumulation of glutamate resulting from inhibition of EAATs 14 or enhanced glutamate release due to the activation of kainate receptors, 15, 22 thus in turn Figure 6 GAPDH is copresent with acetylated histone and decreased by VPA treatment in the ChIP complex. CGC cultured on 10-cm dishes were treated with 1.6 mM VPA on 7, 9, or 11-DIV and treated with 1% formaldehyde on 13-DIV to crosslink histones to DNA. The ChIP assay was then performed using anti-acetylated histone H3 antibody to obtain the protein A agarose/antibody/ acetylated histone H3 complex as described in the Materials and Methods. Western blotting was then performed to probe for total acetylated histone H3 (a), acetylated histone H3 Lys9 (b), and GAPDH (c) in the ChIP complex. The upper panels show the immunoblots and the lower panels show their quantified results expressed as the means7SEM of % of untreated (vehicle) control from three independent experiments. Statistically significant positive correlation was observed in protein levels of total acetylated histone H3 and acetylated histone H3 on lysine 9 (Po0.01), while a significant negative correlation was observed in GAPDH protein levels (Po0.01).
activating NMDA receptors to trigger cell death. However, the lack of kainite-induced death of CGC speaks against the latter possibility. 23 The role of EAATs in SYM-induced apoptosis is further supported by the observations that EAAT inhibitors exacerbate endogenous glutamate-induced excitotoxicity through NMDA receptor activation, 24 and that SYM is one of the most potent inhibitors of EAATs, 14 which are expressed in CGC neurons. 25, 26 Our pioneering studies show that GAPDH overexpression and nuclear translocation is involved in apoptosis of several cell types subjected to various insults. 16, [18] [19] [20] 27 This role of GAPDH in apoptosis is supported by these studies, which demonstrate that GAPDH antisense oligonucleotides suppress GAPDH overexpression and nuclear translocation and protect cells from apoptotic insults. In addition, CGP 3466, a deprenyl derivative, which binds GAPDH, also blocks growth factor deprivation-induced GAPDH nuclear translocation and apoptosis. 28 Our present results provide the first evidence that GAPDH nuclear translocation is associated with excitotoxicity and that VPA neuroprotection is accompanied by suppression of SYM-induced nuclear translocation. Precise mechanisms underlying GAPDH nuclear translocation-mediated apoptosis are unclear, but could be related to a decrease in GAPDH-associated functions such as glycolytic and uracil DNA glycosylase activities following nuclear translocation, 27 or due to interaction with nuclear proteins and alterations in nuclear function in a gain-oftoxicity manner. 20, 29 One such nuclear protein that can possibly interact with GAPDH is NcoR (A Sawa et al. unpublished results).
Our results using ChIP assays, which detect interactions among chromatin-associated proteins, revealed that nuclear GAPDH was copresent with acetylated histone H3 and that long-term VPA caused a decrease in GAPDH in the ChIP complex with a concurrent increase in acetylated histone. It is currently unknown whether GAPDH directly binds histone H3 or GAPDH and histone H3 are located in close vicinity on chromatin and therefore are crosslinked to a common fragment of DNA and co-immunoprecipitated. In any event, our results robustly demonstrate that there is an inverse relationship between the levels of histone H3 acetylation and GAPDH nuclear accumulation in VPAtreated neurons, raising the possibility that enhanced histone acetylation may weaken the association of GAPDH with chromatin. It is conceivable that the free nuclear GAPDH not bound to chromatin will be exported to the cytoplasm. This is based on a recent report that GAPDH nuclear translocation is reversible and a novel exportin1-dependent nuclear export signal (NES) comprising 13 amino acids of the C-terminal domain of GAPDH has been identified. 30 Truncation or mutation of this NES abrogates exportin1 binding and causes nuclear accumulation of GAPDH. It remains to be investigated whether the acetylation of other proteins such as the cell survival transcription factor SP1 is enhanced by VPA under our experimental conditions and, if so, whether their acetylation plays a role in the neuroprotection against excitotoxicity. The much greater decrease in GAPDH elicited by VPA in the ChIP complex than in the nuclear preparation of unstimulated CGC ( Figure 6 vs Figure 5b ) suggests that only a small fraction of nuclear GAPDH is present with histone proteins in the ChIP complex. Interestingly, it was recently reported that the histone H2B promoter interacts with a GAPDHcontaining transcriptional coactivator complex, 31 indicating that nuclear GAPDH may have an important function in gene transcription. GAPDH also selectively interacts with the polyglutamate region of huntingtin, 32 a Huntington's disease protein that accumulates in the nuclei as the pathophysiology progresses. Thus, it seems possible that GAPDH may also function as a chaperone in mediating nuclear translocation of proapoptotic proteins. In a transgenic mouse model of Huntington's disease, we found that the expression and nuclear levels of GAPDH were markedly enhanced in several brain areas affected by this disease. 33 Of further interest, HDAC inhibitors have been reported to reduce polyglutamine-induced toxicity and slow neurodegeneration in a Drosophila model of Huntington's disease. 34 Inhibition of HDAC produces hyperacetylation of histone tails, causing chromatin relaxation due to disruption of histone-DNA and histone-histone interactions (for a review, see Zhang et al 35 ) . As a consequence, gene expression can be activated and sometimes downregulated. 10 VPA-induced hyperacetylation of histone proteins has also been shown in mouse brain studies in vivo. 36, 37 The requirement of protracted pretreatment for HDAC inhibitors to elicit neuroprotective effects in our studies suggests an involvement of changes in gene expression. VPA has been reported to enhance the expression of cytoprotective proteins such as Bcl-2, 38 GRP (glucose-regulated protein), 39 heat-shock protein 70, 40 ,41 and brain-derived neurotrophic factor. 42 It remains to be investigated whether VPA-induced upregulation of these proteins is triggered by HDAC inhibition and whether induction of any of these proteins contributes to VPA neuroprotection against SYM neurotoxicity. 
